Neisseria meningitidis compositions and methods thereof
US-9561269-B2 · Feb 7, 2017 · US
Neisseria meningitidis composition and methods thereof
US2016347797A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016347797-A1 |
| Application number | US-201615237005-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 15, 2016 |
| Priority date | Mar 9, 2012 |
| Publication date | Dec 1, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 68. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal
First claim
Opening claim text (preview).
What is claimed is: 1 . An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is not present, as compared to SEQ ID NO: 15. 2 . The polypeptide according to claim 2 , wherein the sequence comprises SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 15. 3 . The polypeptide according to claim 2 , wherein the sequence comprises SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is substituted, as compared to SEQ ID NO: 15. 4 . The polypeptide according to claim 3 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 64. 5 . The polypeptide according to claim 1 , wherein the polypeptide is immunogenic. 6 . The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry. 7 . The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 68. 8 . The isolated polypeptide according to claim 7 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 69. 9 . The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 64. 10 . The isolated polypeptide according to claim 9 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 63. 11 . An immunogenic composition comprising the polypeptide as in any of claims 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , and 10 . 12 . The composition according to claim 11 , further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 71, wherein an N-terminal cysteine at position 1 is deleted as compared to SEQ ID NO: 70. 13 . The composition according to claim 11 , further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 49, wherein an N-terminal cysteine at position 1 is deleted as compared to SEQ ID NO: 18. 14 . The composition according to claim 11 , further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 76. 15 . The composition according to claim 11 , further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 75. 16 . The composition according to claim 11 , further comprising an adjuvant.
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Antibacterial agents · CPC title
Lipids, e.g. in lipopeptides · CPC title
- C07K14/22Primary
from Neisseriaceae (F) · CPC title
Saponins; Quil A; QS21; ISCOMS · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016347797A1 cover?
- In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 68. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningoc…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).